Early detection of cancer is crucial for successful treatment across various types of cancer. Oncologists utilize imaging and invasive methods like biopsies for diagnosis and monitoring treatment outcomes. Now, researchers have introduced an innovative technique that analyzes DNA fragments in blood samples, providing a less invasive and more efficient way to tailor treatments to individual patients.
Analyzing gene fragments in the bloodstream
At the University of Zurich (UZH) and the University Hospital Zurich (USZ), researchers have developed a cutting-edge liquid biopsy method that examines DNA fragments in blood samples. According to Zsolt Balázs from UZH, this approach can be used for risk assessment, treatment monitoring, and early cancer detection across various tumor types.
This method offers a less invasive alternative to traditional tissue biopsies and allows for quick sample collection, streamlining hospital procedures and reducing patient wait times.
Tailor-made treatment approach
The liquid biopsy analysis can provide precise insights into tumor activity and progression, aiding oncologists in customizing individualized therapies. By detecting genetic changes characteristic of specific cancers, this method enables early assessment of treatment responses and potential relapses.
Researchers can differentiate between aggressive and less aggressive metastatic cancers using this technique, potentially identifying disease progression earlier than with imaging technologies.
Increased focus on patients’ quality of life
Researchers tested the method on patients receiving radiotherapy, particularly those with HPV-positive tumors. By monitoring HPV DNA fragments in the blood, they could track tumor development. In the case of head and neck cancers, higher HPV DNA concentrations indicated potential early cancer recurrence, suggesting the use of immunotherapy.
Balermpas stresses the importance of individualized treatments by considering therapy benefits and their impact on patients’ quality of life, especially in cases of metastatic or recurrent tumors.
